Two of three patients achieved both complete remission and MRD-negative status
High response rates observed in earlier studies continue in ongoing mipletamig trial
Cohort 2 enrollment commencing
https://www.accesswire.com/953864/100-of-patients-achieve-remission-within-30-days-in-cohort-1-of-bispecific-mipletamig-frontline-aml-trial
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.